Emerging Pharmacological and Invasive Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology. [PDF]
Card Fail RevLi-Wen Chu E, Seung Kim D, Masri A.
europepmc +1 more source
Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy
Australian prescriberopenaire +3 more sources
Treatment of Symptomatic Mid-Cavitary Obstruction Hypertrophic Cardiomyopathy With Mavacamten. [PDF]
JACC Case RepZhang X, Ye Q, Chen S, Lu H, Ji X.
europepmc +1 more source
Net health benefit of mavacamten for the treatment of Chinese patients with obstructive hypertrophic cardiomyopathy: a model-based economic evaluation. [PDF]
Front PharmacolBao H +6 more
europepmc +1 more source
Effect of beta‐blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy [PDF]
European Journal of Heart Failure, 2023 Matthew T Wheeler Iii +2 more
exaly +3 more sources
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial [PDF]
Lancet, The, 2020 Artur Oreziak +2 more
exaly +3 more sources
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy [PDF]
Journal of the American College of Cardiology, 2020 BACKGROUND: Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience a high burden of symptoms; however, there are no proven pharmacological therapies.
Carolyn Y Ho +2 more
exaly +3 more sources
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial [PDF]
Lancet, The, 2021 BACKGROUND: Improving symptoms is a primary treatment goal in patients with obstructive hypertrophic cardiomyopathy. Currently available pharmacological options for hypertrophic cardiomyopathy are not disease-specific and are often inadequate or poorly ...
John A Spertus +2 more
exaly +2 more sources